GeoVax Labs (GOVX) FDA Events

GeoVax Labs' Drug in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by GeoVax Labs (GOVX). Over the past two years, GeoVax Labs has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as GEO-CM04S1. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

GEO-CM04S1 FDA Regulatory Events

GEO-CM04S1 is a drug developed by GeoVax Labs for the following indication: For CLL Patients. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Data Presentation - June 17,2025

• Drug: GEO-CM04S1
• Announced Date: June 17, 2025
• Indication: For CLL Patients

GeoVax Labs, Inc. today highlighted new clinical data presented at the 2025 European Hematology Association (EHA) Hybrid Congress which took place June 12-15 in Milan, Italy.

GeoVax Labs FDA Events - Frequently Asked Questions

Has GeoVax Labs received FDA approval?

As of now, GeoVax Labs (GOVX) has not received any FDA approvals for its therapy in the last two years.

What drugs has GeoVax Labs submitted to the FDA?

In the past two years, GeoVax Labs (GOVX) has reported FDA regulatory activity for GEO-CM04S1.

What is the most recent FDA event for GeoVax Labs?

The most recent FDA-related event for GeoVax Labs occurred on June 17, 2025, involving GEO-CM04S1. The update was categorized as "Data Presentation," with the company reporting: "GeoVax Labs, Inc. today highlighted new clinical data presented at the 2025 European Hematology Association (EHA) Hybrid Congress which took place June 12-15 in Milan, Italy."

What conditions do GeoVax Labs' current drugs treat?

Currently, GeoVax Labs has one therapy (GEO-CM04S1) targeting the following condition: For CLL Patients.